MAPK/ERK通路
激活剂(遗传学)
丝裂原活化蛋白激酶
细胞生物学
MAP激酶激酶激酶
c-jun公司
激酶
癌症研究
丝裂原活化蛋白激酶激酶
癌变
生物
蛋白激酶A
功能(生物学)
基因
生物化学
转录因子
作者
Clare C. Davies,Cathy Tournier
出处
期刊:Biochemical Society Transactions
[Portland Press]
日期:2012-01-19
卷期号:40 (1): 85-89
被引量:125
摘要
JNK (c-Jun N-terminal kinase) is a member of the MAPK (mitogen-activated protein kinase) family that regulates a range of biological processes implicated in tumorigenesis and neurodegenerative disorders. For example, genetic studies have demonstrated that the removal of specific Jnk genes can reduce neuronal death associated with cerebral ischaemia. As such, targeting JNK signalling constitutes an obvious opportunity for therapeutic intervention. However, MAPK inhibitors can display toxic effects. Consequently, dual-specificity MKKs (MAPK kinases) may represent more attractive targets. In particular, evidence that blocking JNK activation by removing MKK4 offers an effective therapy to treat pathological conditions has started to emerge. MKK4 was the first JNK activator identified. The remaining level of JNK activity in cells lacking MKK4 expression led to the discovery of a second activator of JNK, named MKK7. Distinct phenotypic abnormalities associated with the targeted deletion of Mkk4 and Mkk7 in mice have revealed that MKK4 and MKK7 have non-redundant function in vivo. Further insights into the specific functions of the JNK activators in cancer cells and in neurons will be of critical importance to validate MKK4 and MKK7 as promising drug targets.
科研通智能强力驱动
Strongly Powered by AbleSci AI